ImmuCell
ICCC
12 hedge funds and large institutions have $1.01M invested in ImmuCell in 2014 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 0 closing their positions.
250% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 2
9% more funds holding
Funds holding: 11 → 12 (+1)
9% less capital invested
Capital invested by funds: $1.1M → $1.01M (-$94K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SKK
Shepherd Kaplan Krochuk
Boston,
Massachusetts
|
+$16.8K |
| 2 |
Wells Fargo
San Francisco,
California
|
+$8.42K |
| 3 |
Renaissance Technologies
New York
|
+$7.58K |
| 4 |
SRC
Shufro Rose & Co
New York
|
+$4.65K |
| 5 |
U
UBS
Zurich,
Switzerland
|
+$3.59K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$36.7K |
| 2 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
-$10.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HP
1
HealthInvest Partners
Stockholm,
Sweden
| $345K | -$10.4K | -2,469 | -3% |
|
|
SRC
2
Shufro Rose & Co
New York
| $233K | +$4.65K | +1,105 | +2% |
|
|
SKK
3
Shepherd Kaplan Krochuk
Boston,
Massachusetts
| $152K | +$16.8K | +4,000 | +13% |
|
|
EFS
4
Essex Financial Services
Essex,
Connecticut
| $105K | – | – | – |
|
|
5
Morgan Stanley
New York
| $77K | -$36.7K | -8,723 | -33% |
|
|
6
Renaissance Technologies
New York
| $68K | +$7.58K | +1,800 | +13% |
|
7
Bank of America
Charlotte,
North Carolina
| $9K | +$177 | +42 | +2% |
|
|
8
Wells Fargo
San Francisco,
California
| $9K | +$8.42K | +2,000 | +200,000% |
|
|
U
9
UBS
Zurich,
Switzerland
| $8K | +$3.59K | +852 | +85% |
|
|
GSC
10
Ground Swell Capital
Folly Beach,
South Carolina
| $2K | +$2.13K | +507 | New |
|
11
Creative Planning
Overland Park,
Kansas
| $1K | – | – | – |
|
|
TRCT
12
Tower Research Capital (TRC)
New York
| $1K | +$1.06K | +251 | +3,586% |
|
ICCC Hedge Fund Activity: Q2 2014 in Review
12 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in ImmuCell (ICCC) for Q2 2014, worth a combined $1.01M — down 8.5% from $1.1M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new ICCC positions and 0 closed out — a net gain of 1 holder — while 7 added to existing stakes and 2 trimmed.
The largest buyer was Shepherd Kaplan Krochuk, adding an estimated $16.8K. The largest seller was Morgan Stanley, cutting an estimated $36.7K.
- 12 institutional investors held ImmuCell (ICCC) as of Q2 2014, up from 11 in Q1 2014.
- Funds reported $1.01M of ImmuCell stock for Q2 2014, down 8.5% quarter-over-quarter.
- 1 fund opened new ImmuCell positions in Q2 2014 and 0 closed out, a net change of +1 holder.
- The largest ImmuCell buyer in Q2 2014 was Shepherd Kaplan Krochuk, an estimated $16.8K added.
- The largest ImmuCell seller in Q2 2014 was Morgan Stanley, an estimated $36.7K sold.
Based on aggregated 13F filings for Q2 2014.